A Phase II Trial of BIBW 2992 as a Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type EGFR.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2014
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Sep 2012 Results presented at the European Society for Medical Oncology meeting, according to a Boehringer Ingelheim media release.
- 16 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 16 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.